|
临床相关性
一级信息 关于临床相关性和缩写列表 |
Clinical Relevance
First level information About Clinical Relevance & List of Abbreviations |
►在抗合成酶抗体综合征 (自身免疫性肌病的一种)、间质性肺病、多发性关节炎、雷诺现象和技工手的患者中可检出；这些特征可能以多种形式或单一形式出现，尤其是间质性肺病 (33, 90) ►所报道的与AC-20核型相关的自身抗体主要为抗Jo-1抗体，该抗体识别组氨酰- tRNA合成酶；由于AC-20不是Jo-1抗体的特异核型，因此推荐后续检测抗Jo-1特异性抗体；抗原包含于常规 ENA 谱和疾病特异性免疫试剂 (即肌炎谱 *)中；抗Jo-1抗体已被纳入自身免疫性肌病分类标准中 (91, 92) 注：AC-19和AC-20之间的细微区别可能取决于HEp-2细胞底物和/或抗体浓度；在HEp-2细胞的间接免疫荧光筛查中可能检测不到针对Jo-1的抗体。 *肌炎谱、系统性硬化症谱和 (扩展的) 肝病谱可能仅限于专业临床实验室应用。 |
► Found in patients with the anti-synthetase syndrome (a subset of AIM), interstitial lung disease, polyarthritis, Raynaud’s phenomenon, and mechanic’s hands; these features may occur in various combinations or as an isolated manifestation, especially interstitial lung disease (33, 90) ► Autoantibodies associated with the AC-20 pattern are primarily reported for the anti-Jo-1 antibody, which recognizes histidyl-tRNA synthetase; since AC-20 is not specific for Jo-1, it is recommended to perform a follow-up test for anti-Jo-1 antibodies; the antigen is included in the routine ENA profile, as well as in disease specific immunoassays (i.e., inflammatory myopathy profile*); the anti-Jo-1 antibodies are included in the classification criteria for AIM (91, 92) Notes: The fine distinction between AC-19 and -20 may depend on HEp-2 substrates and/or antibody concentration; antibodies to Jo-1 may be undetected in HEp-2 IIFA-screening. *Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories. |
| 一级信息参考文献 | First level information references |
33. Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1–19. 90. Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15. 91. Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies. J Rheumatol 2018;45:444.1–5. 92. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76:1955–64. |
33. Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1–19. 90. Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15. 91. Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies. J Rheumatol 2018;45:444.1–5. 92. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76:1955–64. |
| 二级信息 | Second level information |
无 |
None |
| 二级信息参考文献 | Second level information references |
无 |
None |
| FAQ |
| No FAQ received |
Copyright @ ICAP - 2019 Online since 19 May 2015
